Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP (LONN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
261(c) 259.9(c) 256(c) 256.4(c) 258.5 Last
349 514 231 883 361 933 240 491 345 842 Volume
-1.36% -0.42% -1.50% +0.16% +0.82% Change
More quotes
Financials ( CHF)
Sales 2017 5 113 M
EBIT 2017 907 M
Net income 2017 516 M
Debt 2017 4 006 M
Yield 2017 1,11%
Sales 2018 6 011 M
EBIT 2018 1 198 M
Net income 2018 752 M
Debt 2018 3 558 M
Yield 2018 1,31%
P/E ratio 2017 35,70
P/E ratio 2018 26,83
EV / Sales2017 4,52x
EV / Sales2018 3,77x
Capitalization 19 094 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates its business through the Pharma&Biotech and Specialty Ingredients segments.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as... 
Sector
Biotechnology & Medical Research
Calendar
10/26 | 02:30pmSales and Revenue Call
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
10/17 LONZA : Consumer Care Highlights LaraCare ® A200 Naturally Occurring, Multifunct..
10/09 LONZA : Announces Formation of New Research and Development Collaborative Innova..
10/06 LONZA : Showcases Optimized Polyglyceryl Ester Combination, Multifunctional Poly..
10/05 LONZA : Cell & Gene Therapy Manufacturing Facility in Houston, TX, Area to Compl..
10/03 Lonza to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Custom..
10/03 LONZA : to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Custome..
10/03 LONZA TO HOST NEW WEBINAR : “Challenges and Strategies for Paperless Produ..
09/22 LONZA : Groundbreaking for the New Large-Scale Biologics Production Facility in ..
09/19 LONZA : Introduces the New CytoSMART™ 2 System for Live Cell Imaging
09/11 LONZA : Consumer Care Launches Online "Survive the BPR™" Knowledge Centre
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/09Lonza sets up innovation collaboration centre in Israel  
10/09Swiss pharma co Lonza opening Haifa innovation center
1
10/03Lonza buys U.S. clinical manufacturing site from Shire  
10/03Lonza to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Custom.. 
09/28Lonza CFO sees in-house growth, not takeovers, to grow drug services  
More tweets
Qtime:41
News from SeekingAlpha
10/03 Oppenheimer International Growth Fund Inst (OIGYX) September Summary
09/05 Oppenheimer International Growth Fund Inst (OIGYX) August Summary
08/08 Oppenheimer International Growth Fund Inst (OIGYX) July Summary
07/26 Lonza's (LZAGY) CEO Richard Ridinger on Q2 2017 Results - Earnings Call Trans..
07/26 Lonza Group AG reports 1H results
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 278  CHF
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Rolf Soiron Chairman
Marc Funk Chief Operating Officer
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP57.01%19 392
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522
SEATTLE GENETICS, INC.21.30%9 134